Olverembatinib produced progressively deepening cytogenetic and molecular responses in second-line chronic-phase chronic myeloid leukemia.
News|Videos|September 30, 2024 (Updated: October 4, 2024)
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Author(s)Maurice Perol, MD
Maurice Pérol, MD, presents a pooled analysis of two pivotal Phase 2 trials assessing the efficacy and safety of taletrectinib in patients with advanced ROS1+ non-small cell lung cancer.
Advertisement
Advertisement
Related to this article
The phase 3 INTREPID trial is evaluating sapablursen in phlebotomy-dependent polycythemia vera.
The FDA has approved zanidatamab plus chemotherapy with/without tislelizumab in frontline HER2-positive GEA based on data from HERIZON-GEA-01.
MD Anderson Cancer Center recognized outstanding faculty members for their exceptional contributions to cancer research, patient care, prevention, education and leadership.
Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
Patients who received MBTF prior to allo-HSCT achieved promising survival outcomes and manageable safety in relapsed/refractory acute myeloid leukemia.
Sagar Lonial, MD, FACP, FASCO, and Sikander Ailawadhi, MD, discuss the investigation of cemsidomide in relapsed/refractory multiple myeloma.
Mayo Clinic Study Estimates Cancer Risk in Patients With Pancreatic Cysts, Advancing Early Detection
Mayo Clinic researchers have estimated the risk that pancreatic cysts with worrisome or high-risk features will progress to pancreatic cancer or advanced precancerous changes.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zanidatamab-Based Regimens for First-Line HER2+ Locally Advanced or Metastatic Gastric Cancer
2
FDA Grants Fast Track Designation to Pan-RAS Molecular Glue ERAS-0015 for Metastatic Pancreatic Adenocarcinoma
3
FDA Grants Priority Review to Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
4
MOMENTUM Trial Aims to Add Further Evidence for Cemsidomide in R/R Myeloma
5